After completing a number of clinical trials, The MPN community was disappointed when a promising compound in development for myelofibrosis, momelotinib, was discontinued by Gilead Sciences Inc. So, it was a great relief when, in 2018, Sierra Oncology acquired momelotinib with the intention of continuing the development of the drug. Sierra Oncology is planning a… Read More »UPDATE ON PROMISING MF TREATMENT, MOMELOTINIB
A TGF-Beta inhibitor – AVID 200 – is joining the race for new therapies for myeloproliferative neoplasms. In a press release published today, Forbius Biologics Inc. announced that the first myelofibrosis patient has been dosed in their phase 1b myelofibrosis trial of AVID 200, a novel TGF-Beta inhibitor. The investigator-initiated trial is being run by… Read More »CLINICAL TRIAL FOR AVID200 DOSES FIRST MF PATIENT
The MPN Research Foundation is celebrating our first annual Founder’s Day in memory of Robert (Bob) Rosen, the person who started it all almost 20 years ago. Today, May 6th is particularly special as it was Bob’s birthday, and we look forward to celebrating his legacy on this day for years to come. Bob was… Read More »MPNRF celebrates 1st annual Founder’s Day
Researchers in The Tisch Cancer Institute’s Myeloproliferative Neoplasms (MPN) Program at Mount Sinai is investing a novel class of drugs for MPN patients. “Our hope is that idasanutlin will improve long-term survival in patients with chronic blood cancers,” says Dr. Hoffman, MD, at the Icahn School of Medicine at Mount Sinai. He says the mission… Read More »RESEARCHERS AT MOUNT SINAI INVESTIGATE A NOVEL CLASS OF DRUGS FOR MPN PATIENTS
Today the American Society of Clinical Oncology is wrapping up their 2019 ASCO meeting held annually in Chicago, IL. Although ASCO does not focus solely on blood cancers, the MPN Research Foundation looks forward to attending each year to discuss the status of MPN research and treatments with oncology professionals, drug companies, and fellow advocacy groups.… Read More »MPN UPDATES FROM ASCO 2019
Sierra Oncology announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to momelotinib, a JAK1, JAK2, and ACVR1 inhibitor, for the treatment of patients with intermediate/high-risk myelofibrosis. “Fast Track designation for momelotinib highlights the serious and significant unmet needs of patients with myelofibrosis who have previously received a JAK inhibitor.… Read More »POSSIBLE NEW MYELOFIBROSIS DRUG GETS FAST TRACKED BY THE FDA
Presented at the 24th Congress of the European Hematology Association (EHA), Promedior, Inc. announced today that positive safety and early efficacy clinical data was proven during their Phase 2 study of PRM-151 in myelofibrosis (MF) patients who were ineligible for Ruxolitinib or had failed the drug. Promedior looks forward to advancing the clinical program for PRM-151 in both MF and… Read More »PROMEDIOR PRESENTS POSITIVE DATA FROM A PHASE 2 STUDY OF PRM-151 IN MF PATIENTS
How does MDM2 inhibition work to treat myeloproliferative neoplasms (MPNs)? What are the goals of this treatment approach? Renowned experts Dr. Srdan Verstovsek and Dr. Jason Gotlib discuss MDM2 inhibition as an avenue for the treatment of MPNs and share information on an upcoming MDM2 clinical trial for patients living with myelofibrosis (MF) and polycythemia vera… Read More »HOW DOES MDM2 INHIBITION WORK TO TREAT MPNS?
Researchers at the American Association for Cancer Research recently published an article, “Immune Checkpoint Blockade Enhances Shared Neoantigen-Induced T Cell Immunity Directed against Mutated Calreticulin in Myeloproliferative Neoplasms,” highlighting the restoration of T-cells specific to fighting the CALR mutation in MPN patients. Utilization of checkpoint blockades confirmed mut-CALR as an effective immunogen that can be… Read More »PROMISING RESULTS OF NEW AACR STUDY
Since the development of the JAK1/2 inhibitor ruxolitinib, our understanding of MPNs has come a long way. Researchers Bing Li, Raajit K. Rampal, and Zhijian Xiao document the targeted therapies currently in various stages of development, with the promising effects of reducing myelosuppression, greater selectivity for JAK1/2, and the ability to overcome JAK inhibitor persistence.… Read More »THE ADVANCEMENT OF TARGETED THERAPY
